Standard Care and Kidney Protection

Because Fibronectin glomerulopathy (FNG) is a rare genetic condition where abnormal proteins are deposited in the kidney, there is no single “cure” or drug that can remove these deposits. Instead, the standard of care focuses on supportive management—a strategy aimed at lowering the pressure inside your kidneys to protect the remaining healthy filters and slow down the progression of the disease ^[1][2].

The Foundation: RAAS Blockade

A main supportive strategy for FNG involves a class of medications called RAAS inhibitors, which include ACE inhibitors (like lisinopril) and ARBs (like losartan or valsartan) ^[3][4].

These medications do two critical things for your kidneys:

• Lower Blood Pressure: High blood pressure strains your kidney’s delicate filters, causing more damage. Lowering it helps preserve the filters ^[5].
• Reduce Proteinuria: By relaxing the blood vessels leaving the kidney, these drugs reduce the internal pressure that forces protein out of your blood and into your urine. Case reports of FNG patients have shown that this supportive care, extrapolated from broader proteinuric CKD experience, can help stabilize kidney function and reduce protein leakage ^[1][4].
• Safety Note: ACE inhibitors and ARBs should not be combined. You must have your creatinine and potassium monitored after initiation or dose increases.

Managing Fluid and Swelling

If you have edema (swelling) or nephrotic syndrome (very high levels of protein loss), your doctor may prescribe diuretics, often called “water pills” ^[6].

• How They Work: Diuretics help your kidneys flush out extra salt and water, which reduces swelling in your legs and around your eyes ^[7].
• Monitoring: While helpful, these must be monitored closely to ensure you don’t become dehydrated or experience a drop in blood pressure that could temporarily strain your kidneys ^[6].

Evolving Therapies: SGLT2 Inhibitors

A newer class of drugs called SGLT2 inhibitors (such as empagliflozin or dapagliflozin) has become a standard recommendation for many types of chronic kidney disease (CKD) ^[8].

• Broad Benefits: Large clinical trials (like EMPA-KIDNEY) have shown these drugs significantly reduce the risk of kidney disease progression in broad CKD populations ^[9][10].
• Use in FNG: FNG-specific evidence is extremely limited. Using SGLT2 inhibitors for FNG is an extrapolation from general CKD trials. Eligibility depends on eGFR, albuminuria, heart failure or diabetes indications, volume status, and contraindications—not eGFR alone ^[6][8].
• Safety Considerations: Key safety risks include an expected initial dip in eGFR, genital yeast infections, volume depletion, and a rare risk of ketoacidosis. SGLT2 inhibitors require clinician-directed holding during acute illness, fasting, or surgery.

Why Routine Immunosuppression is Usually Avoided

In many other kidney diseases, doctors use immunosuppressants like prednisone. However, for most patients with FNG, routine immunosuppression has no established benefit ^[1][6].

• Not a Primary Immune Disease: Typical FNG is a deposition disorder, not a primary immune-complex disease, though immunoglobulin staining can occasionally occur requiring careful diagnosis ^[11].
• Risks vs. Benefits: Studies have shown that steroids often produce unsatisfactory or inconsistent results in FNG ^[12][13]. Given the side effects of long-term steroid use—such as weight gain, bone loss, and infection risk—most experts prefer to stick with kidney-protective blood pressure medications instead ^[12]. (Note: Never abruptly stop taking steroids without medical guidance if you are already on them.)

Looking Forward: Experimental Research

Scientists are exploring new ways to stop fibronectin from clumping together. For example, laboratory research has looked at tissue-transglutaminase-2 (TG2) inhibitors, which have shown early potential in preclinical settings for reducing protein deposits ^[14]. While these are experimental and not yet available for patients, this preclinical research is part of a growing effort to understand targeted treatments ^[15].

Long-term Outlook and Transplant

If the disease does eventually lead to kidney failure, dialysis and kidney transplantation are effective options. It is important to know that while the fibronectin deposits can sometimes return in a transplanted kidney (recurrence), many patients are still able to maintain a successful transplant for many years ^[16][17]. Regular monitoring of the new kidney is standard practice in these cases, and living related donors must undergo genetic screening before donation ^[18].